Return to homepagePandemic Pact

BioNet - Broadly Protective Coronavirus Vaccine

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022

  • Known Financial Commitments (USD)

    $16,900,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    France

  • Lead Research Institution

    BioNet

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses.1 CEPI will partner with BioNet'Äîa French-Thai vaccine manufacturer and member of the Developing Country Vaccine Manufacturing network (DCVMN)'Äîproviding up to $16.9 million to support preclinical studies, Phase I and Phase II clinical trials, production of necessary clinical trial material, and process and analytical development.